클로자핀 처방 패턴 및 클로자핀 중단과 관련된 임상 요인
Prescribing Pattern of Clozapine and Clinical Factors associated with Discontinuation of Clozapine
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objectives: Clozapine is the drug of choice in treatment-resistant schizophrenia. However, its use is often delayed and a significant proportion of clozapine treated patients fails to respond and experience potentially dangerous side-effects. The aim of this retrospective study was to describe the clinical characteristics of patients started on clozapine and the rate and reason of discontinuation of clozapine. Methods: Medical records of 83 patients started on clozapine during the period of 2012-2016 were reviewed. Results: Clozapine started on patients in chronic phase; the mean age of start was 38.1 years old and the mean number of psychiatric admission was 6.5. A majority (80.7%) of the patients had been subjected to antipsychotic polypharmacy prior to clozapine and most (61.5%) of them were being treated with polypharmacy including clozapine. Overall, 39 (47.0%) subjects had continued clozapine whereas 15 (18.1%) discontinued it; 29 (34.9%) were lost to follow-up. The most common reason for discontinuation was side-effects (n=13) including six life-threatening cases, most of which occurred within 6 months of its start. Conclusion: This study demonstrated that there is some evidence of delays to clozapine use, high rates of polypharmacy and significant rate of discontinuation during the early phase of clozapine treatment.
Abstract
Objectives: Clozapine is the drug of choice in treatment-resistant schizophrenia. However, its use is often delayed and a significant proportion of clozapine treated patients fails to respond and experience potentially dangerous side-effects. The aim of this retrospective study was to describe the clinical characteristics of patients started on clozapine and the rate and reason of discontinuation of clozapine. Methods: Medical records of 83 patients started on clozapine during the period of 2012-2016 were reviewed. Results: Clozapine started on patients in chronic phase; the mean age of start was 38.1 years old and the mean number of psychiatric admission was 6.5. A majority (80.7%) of the patients had been subjected to antipsychotic polypharmacy prior to clozapine and most (61.5%) of them were being treated with polypharmacy including clozapine. Overall, 39 (47.0%) subjects had continued clozapine whereas 15 (18.1%) discontinued it; 29 (34.9%) were lost to follow-up. The most common reason for discontinuation was side-effects (n=13) including six life-threatening cases, most of which occurred within 6 months of its start. Conclusion: This study demonstrated that there is some evidence of delays to clozapine use, high rates of polypharmacy and significant rate of discontinuation during the early phase of clozapine treatment.
참고문헌 (36)
- "National Collaborating Centre for Mental Health (UK) Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014", National Institute for Health and Care Excellence (UK), ~ (2014)
- McIlwain ME, "Pharmacotherapy for treatment-resistant schizophrenia", Neuropsychiatr Dis Treat, 7, pp.135~149 (2011)
- Lewis SW, "Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia", Schizophr Bull, 32, pp.715~723 (2006)
- McEvoy JP, "Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment", Am J Psychiatry, 163, pp.600~610 (2006)
- Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
- Wheeler A, "Outcomes for schizophrenia patients with clozapine treatment: how good does it get?", J Psychopharmacol, 23, pp.957~965 (2009)
- Duggan A, "Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK", Br J Psychiatry, 182, pp.505~508 (2003)
- Brunette MF, "Clozapine use and relapses of substance use disorder among patients with cooccurring schizophrenia and substance use disorders", Schizophr Bull, 32, pp.637~643 (2006)
- Stahl SM, "Clozapine: is now the time for more clinicians to adopt this orphan?", CNS Spectr, 19, pp.279~281 (2014)
- Howes OD, "Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation", Br J Psychiatry, 201, pp.481~485 (2012)
- Tungaraza TE, "Clozapine prescribing in the UK: views and experience of consultant psychiatrists", Ther Adv Psychopharmacol, 5, pp.88~96 (2015)
- Ucok A, "Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia", Int Clin Psychopharmacol, 30, pp.290~295 (2015)
- Yoshimura B, "The critical treatment window of clozapine in treatment-resistant schizophrenia:Secondary analysis of an observational study", Psychiatry Res, 250, pp.65~70 (2017)
- Porcelli S, "Clozapine resistance: augmentation strategies", Eur Neuropsychopharmacol, 22, pp.165~182 (2012)
- Siskind D, "Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-Analysis", Can J Psychiatry, 62, pp.772~777 (2017)
- Wagner E, "Clozapine augmetation strategies-a systematic meta-review of available evidence. Treatment options for clozapine resistance", J Psychopharmacol, 30 (2019)
- Muscatello MRA, "Augmentation strategies in partial responder and", or treatment-resistant schizophrenia patients treated with clozapine, 2014, pp.15, 2329~2345
- Berardis DD, "Safety of antipsychotics for the treatment of schizophrenia:a focus on the adverse effects of clozapine", Ther Adv Drug Saf, 9, pp.237~256 (2018)
- 강시현, "Eosinophilia, Pleural Effusion, Hepatitis, and Jaundice Occurring Early in Clozapine Treatment", Clinical Psychopharmacology and Neuroscience, 11(2), pp.103~105 (2013), 대한정신약물학회
- Thien K, "Delays and barriers to the commencement of clozapine in eligigble people with a psychotic disorder: a literature rievew", Early Interv Psychiatry, 13, pp.18~23 (2019)
- Agid O, "Early use of clozapine for poorly responding first-episode psychosis", J Clin Psychopharmacol, 27, pp.369~373 (2007)
- Thien K, "Clozapine use in early psychosis", Schizophre Res, 199, pp.374~379 (2018)
- 조진우, "클로자핀 중단의 이유", 대한조현병학회지, 19(1), pp.17~24 (2016), 대한조현병학회
- Hayhurst KP, "Postcode prescribing for schizophrenia", Br J psychiatry, 182, pp.281~283 (2003)
- Hayhurst KP, "The cost-effectiveness of clozapine:a controlled, population-based, mirror-image study", J Psychopharmacology, 16, pp.169~175 (2002)
- Munro J, "Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance", Br J Psychiatry, 175, pp.576~580 (1999)
- Davis MC, "Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients", Acta Psychiatr Scand, 130, pp.30~39 (2014)
- Pai NB, "Reason for clozapine cessation", Acta Psychiatr Scand, 125, pp.39~44 (2012)
- Ciapparelli A, "Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study", J Clin Psychiatry, 64, pp.451~458 (2003)
- Laker MK, "Long-term outcome with clozapine:comparison of patients continuing and discontinuing treatment", Int Clin Psychopharmacol, 13, pp.75~78 (1998)
- Harrison J, "Patterns of clozapine prescribing in a mental health service in New Zealand", Pharm World Sci, 32, pp.503~511 (2010)
- Dold M, "Pharmacotherapy of treatment-resistant schizophrenia:a clinical perspective", Evid Based Ment Health, 17, pp.33~37 (2014)
- Chang JS, "Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial", J Clin Psychiatry, 69, pp.720~731 (2008)
- Muscatello MR, "Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study", Schizophr res, 127, pp.93~99 (2011)
- Zheng W, "Clozapine Augmentation With Antiepileptic Drugs for Treatment-Resistant Schizophrenia: A Meta-Analysis of Randomized Controlled Trials", J Clin Psychiatry, 78, pp.e498~e505 (2017)
- Leucht S, "Lithium for schizophrenia revisited:a systematic review and meta-analysis of randomized controlled trials", J Clin Psychiatry, 65, pp.177~186 (2004)